TRIS PHARMA, INC.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2000-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.trispharma.com
Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT03610464
- Locations
- 🇺🇸
Meridien Research, Inc., Maitland, Florida, United States
Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2019-07-22
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03088267
- Locations
- 🇺🇸
Center for Psychiatry and Behavioral Medicine, Las Vegas, Nevada, United States
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)
- Conditions
- Interventions
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 108
- Registration Number
- NCT02083783
- Locations
- 🇺🇸
Bayou City Research, Houston, Texas, United States
🇺🇸Westex Clinical Investigation, Lubbock, Texas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
CORAL XT - Open-label Extension Trial of the CORAL Trial
- First Posted Date
- 2014-01-09
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 76
- Registration Number
- NCT02031432
- Locations
- 🇧🇬
BG008, Sofia, Bulgaria
🇧🇪BE001, Sint-Niklaas, Belgium
🇧🇬BG001, Shumen, Bulgaria
CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT01964378
- Locations
- 🇭🇺
HU004, Gyula, Hungary
🇧🇬BG003, Sofia, Bulgaria
🇧🇬BG004, Varna, Bulgaria
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 699
- Registration Number
- NCT01939366
- Locations
- 🇦🇹
AT001, Vienna, Austria
🇦🇹AT004, Senftenberg, Austria
🇦🇹AT003, Vienna, Austria
Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.
- Conditions
- Interventions
- First Posted Date
- 2012-11-12
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 1089
- Registration Number
- NCT01725087
- Locations
- 🇫🇮
FI005, Kokkola, Finland
🇦🇹AT001, Wien, Austria
🇦🇹AT005, Wien, Austria
Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 619
- Registration Number
- NCT01709214
- Locations
- 🇺🇸
Site 011, Bradenton, Florida, United States
🇺🇸Site 061, Fresno, California, United States
🇺🇸Site 043, Tustin, California, United States
Assessment of GRT6005 in Painful Osteoarthritis of the Knee
- Conditions
- Interventions
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 207
- Registration Number
- NCT01357837
- Locations
- 🇦🇹
Site 3604, Linz, Austria
🇦🇹Site 3605, Senftenberg, Austria
🇦🇹Site 3603, Wien, Austria
Safety and Efficacy of GRT6005 in Pain Due to Diabetic Polyneuropathy
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Tris Pharma, Inc.
- Target Recruit Count
- 189
- Registration Number
- NCT01347671
- Locations
- 🇩🇪
Site 4112, Aschaffenburg, Germany
🇩🇪Site 4109, Bad Oeynhausen, Germany
🇩🇪Site 4101, Berlin, Germany